GENE ONLINE|News &
Opinion
Blog

2022-06-29| Trials & Approvals

Sanofi’s New Pompe Disease Treatment Wins Approval in Europe

by Joy Lin
Share To

Sanofi’s Nexviadyme has been approved by the European Commission as a treatment for Pompe Disease, a rare progressive disease that attacks the heart and skeletal muscles. The marketing greenlight is a boost to Sanofi’s ambitions of making Nexviadyme the new standard of care for Pompe community.

The enzyme replacement therapy, also known as avaglucosidase alfa, is the first approved medicine for Pompe disease in Europe since 2006, following the marketing authorization of Myozyme (alglucosidase alfa), also developed by Sanofi.

 

How Nexviadyme Treats Pompe Disease

 

Pompe disease is caused by a deficiency of alpha-glucosidase, an enzyme required to break down glycogen. Without the enzyme, glycogen accumulates to toxic levels, damaging muscle cells. The disease presents itself in two forms: a severe form that rapidly takes hold in infancy and a late-onset form that progressively damages the muscles over time. 

Nexviadyme is a recombinant form of alpha-glucosidase that binds the mannose-6-phosphate (M6P) receptor, part of the key pathway for glycogen breakdown. Its affinity for M6P is said to be higher than its predecessor Myozyme. By taking on the function of the deficient alpha-glucosidase, Nexviadyme aims to improve uptake and enhance glycogen clearance in target tissues. 

In the Comet study comparing Nexviadyme to Myozyme in late-onset Pompe disease at 49 weeks, Nexviadyme met the primary endpoint of improving respiratory function after patients treated with Nexviadyme showed a 2.9% improvement from baseline in forced vital capacity. The improvement was 2.4% greater than that of the Myozyme group.

On muscle function, patients treated with Nexviadyme walked 32.2m farther compared to baseline in a walking test, the trial’s secondary endpoint. This was 30m farther than the change observed with Myozyme. 

In another study evaluating Nexviadyme in infantile-onset Pompe disease, patients experienced improvements in motor functions and left ventricle mass z-score (LVMZ). 

Common side effects of Nexviadyme include headache, dizziness, tiredness, nausea, and vomiting. 

Related article: America’s Ongoing Battle For Lower Insulin Prices 

 

A Contested Standard of Care 

 

While approved for marketing in Europe, Nexviadyme has been rejected by the EU’s drug regulator as a new active substance (NAS), either due to its similarity in molecular structure, clinical efficacy or safety to Myozyme. Furthermore, Nexviadyme was also recommended to be removed from the Community Register of Orphan Medical products. 

 The rejection is a blow to Sanofi as NAS products could benefit from up to 10 years of market exclusivity, shielding it against generic competition. The French drug giant has challenged the ruling and requested the re-examination of the CHMP opinion on Nexviadyme’s NAS status. 

The Pompe disease treatment has been widely accepted in multiple markets around the world, such as the EU, the US, Japan, and Canada among others. Sales of Nexviadyme reached $31.5 million in Q1 2022. Sales of Myozyme decreased 3% to $247 million as Sanofi switched the treatment of Myozyme to Nexviadyme in the US. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
Insilico Makes its Biggest AI Deal Ever with Sanofi for Potential $1.2 Billion
2022-11-09
The First Approved RSV Vaccine Worldwide Belongs to AstraZeneca and Sanofi
2022-11-06
LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!